CVE-2007-3822

Public Exploit

Description

Multiple cross-site scripting (XSS) vulnerabilities in Webcit before 7.11 allow remote attackers to inject arbitrary web script or HTML via (1) the who parameter to showuser; and other vectors involving (2) calendar mode, (3) bulletin board mode, (4) room names, and (5) uploaded file names.

2.6

CVSS

Severity: Low

CVSS 2.0 •

EPSS 7.07% Top 10%

Third-Party Advisory securityreason.com Third-Party Advisory secunia.com

Affected: n/a n/a

References

Link	Tags
http://osvdb.org/38179	vdb entry
http://osvdb.org/38177	vdb entry
http://osvdb.org/38180	vdb entry
http://www.securityfocus.com/bid/24913	vdb entry exploit
http://securityreason.com/securityalert/2890	third party advisory
http://osvdb.org/38178	vdb entry
http://www.securityfocus.com/archive/1/473714/100/0/threaded	mailing list
http://secunia.com/advisories/26090	third party advisory
https://exchange.xforce.ibmcloud.com/vulnerabilities/35433	vdb entry
http://osvdb.org/38176	vdb entry

Frequently Asked Questions

What is the severity of CVE-2007-3822?: CVE-2007-3822 has been scored as a low severity vulnerability.
How to fix CVE-2007-3822?: To fix CVE-2007-3822, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2007-3822 being actively exploited in the wild?: It is possible that CVE-2007-3822 is being exploited or will be exploited in a near future based on public information. According to its EPSS score, there is a ~7% probability that this vulnerability will be exploited by malicious actors in the next 30 days.

This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.